HER2-positive early breast cancer is a heterogenous disease. We assessed the role of body mass index (BMI) and hormone receptors (HRs) in 238 women who completed adjuvant chemotherapy and 1 year of treatment with trastuzumab. Three-year recurrence risk resulted as higher for HR-negative (HR−) patients with BMI ≥25 compared with HR+ patients with BMI <25, suggesting that this particular subpopulation of patients might benefit from escalation approaches in adjuvant treatment.

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients / Cantini, L.; Pistelli, M.; Merloni, F.; Fontana, A.; Bertolini, I.; De Angelis, C.; Bastianelli, L.; Della Mora, A.; Santinelli, A.; Savini, A.; Maccaroni, E.; Diodati, L.; Falcone, A.; Berardi, R.. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 20:1(2020), pp. e89-e98. [10.1016/j.clbc.2019.06.008]

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients

Cantini L.;Pistelli M.;Merloni F.;Bastianelli L.;Della Mora A.;Santinelli A.;Savini A.;Maccaroni E.;Berardi R.
2020-01-01

Abstract

HER2-positive early breast cancer is a heterogenous disease. We assessed the role of body mass index (BMI) and hormone receptors (HRs) in 238 women who completed adjuvant chemotherapy and 1 year of treatment with trastuzumab. Three-year recurrence risk resulted as higher for HR-negative (HR−) patients with BMI ≥25 compared with HR+ patients with BMI <25, suggesting that this particular subpopulation of patients might benefit from escalation approaches in adjuvant treatment.
2020
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/277564
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact